Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 31Lymphoma 19Neoplasms, Plasma Cell 16Myelodysplastic Syndromes 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 13Leukemia, Myeloid, Acute 13Leukemia 13Hodgkin Disease 12Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Retinoblastoma 6Lymphoma, Mantle-Cell 6Burkitt Lymphoma 6Myeloproliferative Disorders 5Immunoglobulin Light-chain Amyloidosis 5Recurrence 4Primary Myelofibrosis 4Ovarian Neoplasms 4Neuroblastoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Juvenile 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hematologic Neoplasms 4Congenital Abnormalities 4Sezary Syndrome 3Myelodysplastic-Myeloproliferative Diseases 3

Interventions

Ipilimumab 4tremelimumab 1tilsotolimod 1durvalumab 1Vemurafenib 1Vaccination 1Surgical Procedures, Operative 1Nivolumab 1Melphalan 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Diabetes Mellitus, Insulin-Dependent, 12 × Melphalan × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡